文献速递免疫规划传染病防控与疫情报告

澳大利亚维多利亚州与COVID-19疫苗有时序关联的吉兰-巴雷综合征

Guillain-Barré syndrome temporally associated with COVID-19 vaccines in Victoria, Australia.
PubMed 文献 · Vaccine · 2022-11-07

该研究分析了2021年2月至11月澳大利亚维多利亚州主动监测系统收到的COVID-19疫苗接种后吉兰-巴雷综合征(GBS)报告,采用Brighton协作组病例定义和GBS残疾评分,并与ICD10-AM G61.0编码住院背景率比较。共报告41例,其中Vaxzevria 38例、Comirnaty 3例、Spikevax 0例;仅Vaxzevria首剂后观察发生率1.85/10万剂高于背景预期0.39/10万成人住院。

要点

  • Vaxzevria首剂后GBS观察报告率为1.85/10万剂,高于背景预期0.39/10万成人住院。
  • 38例Vaxzevria后GBS中,接种中位年龄66岁,症状中位起病14天,1例死亡。
  • 4例初始分类为GBS后重新分类为急性起病慢性炎症性脱髓鞘性多神经病。

核心结论

  • 仅Vaxzevria首剂后GBS观察发生率超过背景预期率,需全球进一步研究以明确不同疫苗平台相关不良事件的风险因素与临床变异。

研究设计与样本

  • 2021年2月至11月澳大利亚维多利亚州主动监测系统SAEFVIC收到的COVID-19疫苗接种后GBS报告病例系列。
  • 采用Brighton协作组病例定义描述诊断确定性,GBS残疾评分分级严重程度。
  • 将观察GBS发生率与ICD10-AM G61.0编码住院背景率比较。

主要发现

  • 共报告41例GBS:Vaxzevria 38例、Comirnaty 3例、Spikevax 0例。
  • Vaxzevria首剂后观察报告率1.85/10万剂,高于接种后42天内预期0.39/10万成人住院率。
  • 38例Vaxzevria后GBS中,接种中位年龄66岁,症状中位起病14天,1例死亡。
  • 4例初始分类为GBS后重新分类为急性起病慢性炎症性脱髓鞘性多神经病。
  • 随访时疲劳为主要持续症状。

局限性

  • 需全球进一步研究以明确风险因素、临床变异,并提供不同疫苗平台相关GBS等不良事件风险的精确性与普遍性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Guillain-Barré syndrome (GBS) is an adverse event of special interest (AESI) for surveillance systems monitoring adverse events following immunisation (AEFI) with COVID-19 vaccines. Emerging data support a temporal association between GBS and adenovirus-vector COVID-19 vaccines. We present a case series of GBS reports submitted between February and November 2021 to our enhanced spontaneous surveillance system (SAEFVIC) in Victoria, Australia, following vaccination with either the adenovirus-vector vaccine Vaxzevria ChadOx1-S (AstraZeneca) or an mRNA vaccine (Comirnaty BNT162b2 [Pfizer-BioNTech] or Spikevax mRNA-1273 [Moderna]). For each report, Brighton Collaboration case definitions were used to describe diagnostic certainty. Severity was graded using the GBS Disability Score. The observed incidence of GBS following immunisation against COVID-19 was compared to expected background ICD10-AM G61.0 coded hospitalisations. There were 41 total cases of GBS reported to SAEFVIC following Vaxzevria (n = 38), Comirnaty (n = 3), or Spikevax (n = 0) vaccines. The observed GBS incidence rate exceeded the expected background rate for Vaxzevria only, with 1.85 reports per 100,000 doses following dose 1, higher than the expected rate of 0.39 hospital admissions per 100,000 adults within 42 days of vaccination. Of 38 GBS reports following Vaxzevria, the median age at vaccination was 66 years and median onset of symptoms was 14 days following immunisation. There was one death. Four cases initially categorised as GBS were later reclassified as acute-onset chronic inflammatory demyelinating polyneuropathy. Fatigue was the predominant persisting symptom reported at follow up. Additional global studies are required to characterise risk factors, clinical variability, and to provide precision and generalizability regarding AEFI risks such as GBS associated with different vaccine platforms, which will help inform communication of the potential benefits and risks of COVID19 vaccination.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Osowicki J, Morgan HJ, Harris A, et al. Guillain-Barré syndrome temporally associated with COVID-19 vaccines in Victoria, Australia. Vaccine. 2022. PMID: 36357291. doi:10.1016/j.vaccine.2022.10.084

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。